A 10-year supply deal with AmerisourceBergen will give Walgreen new muscle in negotiating drug prices, including for generic drugs, and could force other suppliers to form their own partnerships, analysts say. "In essence, the deal creates pressure on companies that aren't adjoined with others up or down the drug-supply chain," write Timothy Martin and Jon Kamp.

Related Summaries